AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$90.02
−$6.90 (−7.12%) 4:00 PM ET
After hours$89.00
−$1.02 (−1.13%) 6:55 PM ET
Prev closePrevC$96.92
OpenOpen$96.80
Day highHigh$96.80
Day lowLow$87.05
VolumeVol2,662,638
Avg volAvgVol1,254,749
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Sector
Healthcare
AI report sections
BEARISH
MRUS
Merus N.V.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
−100% (Below avg)
Vol/Avg: 0.00×
RSI
11.69(Oversold)
Oversold (<30)
0255075100
MACD momentum
Intraday
+0.00 (Neutral)
MACD: 0.00 Signal: 0.00
Short-Term
-0.47 (Weak)
MACD: -0.23 Signal: 0.24
Long-Term
-0.31 (Weak)
MACD: 0.23 Signal: 0.54
Intraday trend score
16.70
LOW16.70HIGH16.70
Latest news
MRUS•12 articles•Positive: 4Neutral: 8Negative: 0
PositiveBenzinga• Prnewswire
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Emerging immunotherapy technologies are transforming treatment for gastrointestinal cancers, with companies developing novel combination strategies to activate immune responses in historically resistant tumors. The global cancer immunotherapy market is projected to reach $443.17 billion by 2030.
Entered global collaboration with Halozyme to develop subcutaneous formulation of petosemtamab, showing encouraging results across solid tumor cancers
NeutralGlobeNewswire Inc.• Genmab A/S
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Genmab has successfully acquired 94.2% of Merus N.V.'s outstanding shares at $97 per share, adding petosemtamab to its portfolio and positioning itself for potential billion-dollar revenue by 2029.
Acquired by Genmab, shareholders receive $97 per share with potential for further transactions
NeutralGlobeNewswire Inc.• Genmab A/S
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes
Genmab A/S has completed a $2.5 billion notes offering, including $1.5 billion in senior secured notes and $1.0 billion in senior unsecured notes, to fund its acquisition of Merus N.V. and related expenses.
Being acquired, which suggests potential value but lacks specific details about the acquisition's strategic implications
NeutralGlobeNewswire Inc.• Halper Sadeh Llc
Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Shareholders to Contact the Firm to Discuss Their Rights
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for three companies involved in merger and acquisition transactions.
EXASNVRIMRUSsecurities lawmergersacquisitionsshareholder rights
Sentiment note
Being acquired by Genmab A/S for $97.00 per share, with law firm investigating potential legal issues
PositiveGlobeNewswire Inc.• Merus N.V.
Tussentijdse gegevens van Merus over petosemtamab bij gemetastaseerde colorectale kanker tonen monotherapie-activiteit en robuust responspercentage aan in combinatie met FOLFOX/FOLFIRI, alsook goed verdragen veiligheid
Merus reported positive interim clinical data for petosemtamab, a bispecific antibody targeting EGFR and LGR5, showing 100% response rate in first-line left-sided metastatic colorectal cancer and 62% response rate in second-line treatment, with a manageable safety profile.
Company reported promising interim clinical data with high response rates and good safety profile for its experimental drug petosemtamab in metastatic colorectal cancer, indicating potential breakthrough treatment
PositiveGlobeNewswire Inc.• Merus N.V.
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
Merus reported promising interim clinical data for petosemtamab, a bispecific antibody targeting EGFR and LGR5, showing high response rates in metastatic colorectal cancer when combined with chemotherapy and as a monotherapy.
The company reported strong interim clinical data with 100% response rate in first-line left-sided metastatic colorectal cancer and 62% response rate in second-line treatment, indicating promising therapeutic potential for their drug petosemtamab
PositiveGlobeNewswire Inc.• Merus N.V.
Op de AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics kondigt Merus de publicatie aan van het abstract over petosemtamab in gemetastaseerde colorectale kanker
Merus presented initial phase 2 clinical trial data for petosemtamab, a bispecific antibody targeting metastatic colorectal cancer, showing promising early results in combination with chemotherapy and as a monotherapy across different treatment lines.
Company reported encouraging early clinical trial results with promising antitumor activity and manageable safety profile for petosemtamab across multiple treatment lines of metastatic colorectal cancer
NeutralGlobeNewswire Inc.• Halper Sadeh Llc
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates PINC, ODP, PRO, MRUS on Behalf of Shareholders
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches related to several company sales, including transactions involving Premier, ODP, PROS Holdings, and Merus.
Sale to Genmab A/S at $97.00 per share, under investigation but no clear indication of wrongdoing
NeutralGlobeNewswire Inc.• Halper Sadeh Llc
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRO, EA, MRUS on Behalf of Shareholders
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches related to recent corporate sales involving PROS Holdings, Electronic Arts, and Merus N.V.
Potential sale to Genmab A/S at $97.00 per share being examined for potential shareholder concerns
NeutralGlobeNewswire Inc.• Juan Monteverde
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger – VRNT, EA, MRUS, and The Farmers Savings Bank
Law firm Monteverde & Associates is investigating potential legal actions related to merger transactions for several companies, offering shareholders free consultation about their rights and potential claims.
Being sold to GEnmad A/S at $97.00 per share, with legal investigation suggesting potential shareholder concerns
NeutralBenzinga• Globe Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders
Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for four companies undergoing sales or mergers, offering shareholders legal consultation about their rights.
Under investigation for a sale to Genmab A/S at $97.00 per share, indicating potential procedural review
NeutralGlobeNewswire Inc.• Halper Sadeh Llc
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies undergoing significant corporate transactions.
Proposed sale to Genmab A/S at $97.00 per share under legal review
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
